Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

Overview

Patients with Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with dynamic allodynia of the lower extremities, patients with Type I or II diabetes and pain distal symmetric sensorimotor polyneuropathy with no dynamic allodynia of the lower extremities, or patients with idiopathic distal predominantly sensory neuropathy participated in a Phase IV clinical trial to assess the efficacy of lidocaine patches in treating painful diabetic neuropathy or idiopathic distal sensory neuropathy.

Full Title of Study: “A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2003

Interventions

  • Drug: Lidoderm
    • Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.

Arms, Groups and Cohorts

  • Experimental: (1) Lidoderm
    • (1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain

Clinical Trial Outcome Measures

Primary Measures

  • Mean change from baseline to Week 3 in average pain intensity as measured from patient diaries using Brief Pain Inventory Question 5.
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)

Secondary Measures

  • McGill Pain Questionnaire
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)
  • Other Pain Questions in BPI
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)
  • Weekly pain intensity/relief measures
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)
  • Pain duration using questions that assess duration and frequency of pain
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)
  • Assessment of allodynia
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)
  • Neuropathy Pain Scale
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)
  • Assessment of safety was based on AEs, skin assessment, physical examination, vital signs, clinical laboratory data, and plasma lidocaine levels
    • Time Frame: Visits – V2 (Day 0), V3 (Day 7), V4 (Day 21), V5 (Day 35), V6/EOs (Day 56)

Participating in This Clinical Trial

Inclusion Criteria

  • At Sites 1, 2, and 3 – Had painful diabetic polyneuropathy of 3 or more months duration – At Site 1 only – Had clinical signs and symptoms of distal predominantly sensory polyneuropathy of 3 or more months duration. Diagnosis of predominantly sensory polyneuropathy were to be confirmed by either nerve conduction studies (large fiber sensory or sensorimotor axonal neuropathy) or by abnormal epidermal innervations on punch skin biopsy (distal leg/proximal thigh) (Herrmann et al., 1999; Holland et al., 1997) – Had an average daily pain rating for the baseline week of pain ratings equal to 4 or greater on the 0 to 10 numerical pain rating scale – Had at least 2 hours of moderate or severe pain intensity due to polyneuropathy daily in the immediately prior 3-month period – Were using stable analgesic drug therapy for at least 1 week (regimen and dosages) prior to screening visit, with the exception of acetaminophen and lidocaine for patients undergoing a punch skin biopsy Exclusion Criteria:

  • Had prior treatment with topical lidocaine, except for use with the punch skin biopsy procedure – Were currently under treatment with Class I antiarrhythmic agents (such as tocainide and mexiletine) – Had any other pain more severe than the painful diabetic or idiopathic neuropathy – Had open skin lesions in the area where the lidocaine patches were to be applied

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Endo Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sr. Director, Clinical R&D, Endo Pharmaceuticals Inc.
  • Overall Official(s)
    • Study Director, Study Director, Endo Pharmaceuticals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.